70
Participants
Start Date
August 25, 2021
Primary Completion Date
May 31, 2023
Study Completion Date
May 31, 2023
Ketamine Hydrochloride
Ketamine is a high trapping NMDA receptor antagonist which has rapid and reliable antidepressant effects in patients with major depressive disorder (MDD) who have failed to respond to conventional monoaminergic agents.
No intervention (placebo)
Placebo injection (0.9% sodium chloride)
RECRUITING
University of Oxford, Oxford
Collaborators (1)
Medical Research Council
OTHER_GOV
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
INDUSTRY
University of Oxford
OTHER